US: 1.646.568.9797 (24x5)
UK: 44.330.808.0580 (24x5)
Worldwide: 91.703.051.960 (24x7)
Anti-obesity drugs are pharmacological agents that reduce or control weight. These drugs alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories. The main treatment modalities for overweight and obese individuals remain dieting and physical exercise. The report analysts forecast the Global Anti-obesity Drugs market to grow at a CAGR of 41.45 percent over the period 2013-2022. The global Anti-obesity Drugs market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Anti-obesity Drugs volume and value at global level, regional level and company level. From a global perspective, this report represents overall Anti-obesity Drugs market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
- Novo Nordisk
- Arena Pharmaceuticals
- Orexigen Therapeutics
- Boehringer Ingelheim
Segment by Regions
- North America
Segment by Type
- Peripherally Acting Anti-obesity Drugs
- Centrally Acting Anti-obesity Drugs
Segment by Application
In Aug 2020,Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Hanmi Pharmaceutical today announced that the companies have entered into an exclusive licensing agreement for the development, manufacture and commercialization of efinopegdutide (formerly HM12525A),Hanmi’s investigational once-weekly glucagon-like peptide-1 (GLP-1)/glucagon receptor dual agonist, for the treatment of nonalcoholic steatohepatitis (NASH). Under the agreement, Merck will be granted an exclusive license to develop, manufacture and commercializeefinopegdutidein the United States and globally. Hanmi will receive an upfront payment of $10 million and is eligible to receive milestone payments up to $860 million associated with the development, regulatory approval and commercialization of efinopegdutide,as well as double-digit royalties on sales of approved product. Hanmi retains an option to commercialize efinopegdutide in Korea. Efinopegdutide is a GLP-1/glucagon receptor dual agonist, which activates both the GLP-1 and glucagon receptors. The safety and efficacy of efinopegdutide has previously been evaluated in multiple Phase 1 and Phase 2 clinical trials, including for the treatment of severely obese individuals with and without type 2 diabetes mellitus.
Research Methodology: Global Metabolic Disorder Therapeutics Market
- Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
- Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
- Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among others.
Table of Contents Executive Summary 1 Anti-obesity Drugs Market Overview 1.1 Product Overview and Scope of Anti-obesity Drugs 1.2 Anti-obesity Drugs Segment by Type 1.2.1 Global Anti-obesity Drugs Production Growth Rate Comparison by Type (2014-2025) 1.2.2 Peripherally Acting Anti-obesity Drugs 1.2.3 Centrally Acting Anti-obesity Drugs 1.3 Anti-obesity Drugs Segment by Application 1.3.1 Anti-obesity Drugs Consumption Comparison by Application (2014-2025) 1.3.2 Kids 1.3.3 Adults 1.3 Global Anti-obesity Drugs Market by Region 1.3.1 Global Anti-obesity Drugs Market Size Region 1.3.2 North America Status and Prospect (2014-2025) 1.3.3 Europe Status and Prospect (2014-2025) 1.3.4 China Status and Prospect (2014-2025) 1.3.5 Japan Status and Prospect (2014-2025) 1.3.6 Southeast Asia Status and Prospect (2014-2025) 1.3.7 India Status and Prospect (2014-2025) 1.4 Global Anti-obesity Drugs Market Size 1.4.1 Global Anti-obesity Drugs Revenue (2014-2025) 1.4.2 Global Anti-obesity Drugs Production (2014-2025) 2 Global Anti-obesity Drugs Market Competition by Manufacturers 2.1 Global Anti-obesity Drugs Production Market Share by Manufacturers (2014-2019) 2.2 Global Anti-obesity Drugs Revenue Share by Manufacturers (2014-2019) 2.3 Global Anti-obesity Drugs Average Price by Manufacturers (2014-2019) 2.4 Manufacturers Anti-obesity Drugs Production Sites, Area Served, Product Types 2.5 Anti-obesity Drugs Market Competitive Situation and Trends 2.5.1 Anti-obesity Drugs Market Concentration Rate 2.5.2 Anti-obesity Drugs Market Share of Top 3 and Top 5 Manufacturers 2.5.3 Mergers & Acquisitions, Expansion 3 Global Anti-obesity Drugs Production Market Share by Regions 3.1 Global Anti-obesity Drugs Production Market Share by Regions 3.2 Global Anti-obesity Drugs Revenue Market Share by Regions (2014-2019) 3.3 Global Anti-obesity Drugs Production, Revenue, Price and Gross Margin (2014-2019) 3.4 North America Anti-obesity Drugs Production 3.4.1 North America Anti-obesity Drugs Production Growth Rate (2014-2019) 3.4.2 North America Anti-obesity Drugs Production, Revenue, Price ... | read more...